HRP20180664T1 - Nova protutijela protiv receptora fc-gama iib i njihova upotreba - Google Patents

Nova protutijela protiv receptora fc-gama iib i njihova upotreba

Info

Publication number
HRP20180664T1
HRP20180664T1 HRP20180664TT HRP20180664T HRP20180664T1 HR P20180664 T1 HRP20180664 T1 HR P20180664T1 HR P20180664T T HRP20180664T T HR P20180664TT HR P20180664 T HRP20180664 T HR P20180664T HR P20180664 T1 HRP20180664 T1 HR P20180664T1
Authority
HR
Croatia
Prior art keywords
novel anti
gamma receptor
receptor iib
antibodies
iib antibodies
Prior art date
Application number
HRP20180664TT
Other languages
English (en)
Inventor
Peter Sondermann
Thomas Pohl
Dominik TER MEER
Anna Carle
Daniela Ehehalt
Nicole Rieth
Original Assignee
Suppremol Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suppremol Gmbh filed Critical Suppremol Gmbh
Publication of HRP20180664T1 publication Critical patent/HRP20180664T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HRP20180664TT 2013-08-16 2018-04-25 Nova protutijela protiv receptora fc-gama iib i njihova upotreba HRP20180664T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13004094.2A EP2837637A1 (en) 2013-08-16 2013-08-16 Novel anti-FcyRIIB IgG-type antibody
EP14755987.6A EP3033357B1 (en) 2013-08-16 2014-08-13 Novel anti-fc-gamma receptor iib antibodies and uses thereof
PCT/EP2014/002234 WO2015022077A1 (en) 2013-08-16 2014-08-13 Novel anti-fc-gamma receptor iib antibodies and uses thereof

Publications (1)

Publication Number Publication Date
HRP20180664T1 true HRP20180664T1 (hr) 2018-07-13

Family

ID=49000296

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180664TT HRP20180664T1 (hr) 2013-08-16 2018-04-25 Nova protutijela protiv receptora fc-gama iib i njihova upotreba

Country Status (24)

Country Link
US (1) US10407499B2 (hr)
EP (2) EP2837637A1 (hr)
JP (2) JP6775420B2 (hr)
KR (1) KR102385790B1 (hr)
CN (1) CN105636987B (hr)
AU (1) AU2014308143B2 (hr)
BR (1) BR112016003030A2 (hr)
CA (1) CA2921251C (hr)
CL (1) CL2016000349A1 (hr)
DK (1) DK3033357T3 (hr)
EA (1) EA035855B1 (hr)
ES (1) ES2668482T3 (hr)
HK (1) HK1224302A1 (hr)
HR (1) HRP20180664T1 (hr)
HU (1) HUE038977T2 (hr)
IL (1) IL244135B (hr)
MX (1) MX2016002027A (hr)
MY (1) MY174711A (hr)
NO (1) NO3033357T3 (hr)
PL (1) PL3033357T3 (hr)
PT (1) PT3033357T (hr)
SG (1) SG11201600930RA (hr)
SI (1) SI3033357T1 (hr)
WO (2) WO2015022077A1 (hr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
MY180940A (en) * 2014-08-13 2020-12-14 Suppremol Gmbh Novel antibodies directed to fc gamma receptor iib and fc epsilon receptor
JP7328243B2 (ja) * 2018-03-26 2023-08-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療薬を試験するためのヒト化げっ歯類

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
DE10157290A1 (de) 2001-11-22 2003-06-05 Max Planck Gesellschaft Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III
ATE536188T1 (de) 2002-08-14 2011-12-15 Macrogenics Inc Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
AU2003265522A1 (en) * 2003-08-18 2005-03-10 Macrogenics, Inc. FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
EP1709073B1 (en) 2003-11-26 2011-08-10 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. SUBSTANCE BINDING HUMAN IgG Fc RECEPTOR IIb (FcgammaRIIb)
JP5367982B2 (ja) * 2004-04-16 2013-12-11 マクロジェニクス,インコーポレーテッド FcγRIIB特異的抗体とその利用法
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB-特异性抗体及其使用方法
CN1997667A (zh) * 2004-05-10 2007-07-11 宏观基因有限公司 人源化FcγRⅡB特异性抗体及其使用方法
WO2007068047A1 (en) 2005-12-13 2007-06-21 Trillium Therapeutics Inc Multimeric fc receptor polypeptides
EP1870422A1 (en) 2006-06-20 2007-12-26 SuppreMol GmbH Means for the treatment of diseases characterized by an excessive immune reaction
CN103275227B (zh) 2007-11-12 2015-02-11 U3制药有限公司 Axl抗体
US8802089B2 (en) * 2008-01-03 2014-08-12 Genmab A/S Monoclonal antibodies against CD32B
JP2011526154A (ja) 2008-06-27 2011-10-06 ザイモジェネティクス, インコーポレイテッド 可溶性ハイブリッドFcγレセプターおよび関連する方法
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
EP2837637A1 (en) * 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
MY180940A (en) 2014-08-13 2020-12-14 Suppremol Gmbh Novel antibodies directed to fc gamma receptor iib and fc epsilon receptor

Also Published As

Publication number Publication date
KR20160036631A (ko) 2016-04-04
CA2921251C (en) 2023-01-24
CN105636987B (zh) 2020-07-31
EP3033357A1 (en) 2016-06-22
CN105636987A (zh) 2016-06-01
CA2921251A1 (en) 2015-02-19
BR112016003030A2 (pt) 2017-09-12
JP2020048562A (ja) 2020-04-02
MY174711A (en) 2020-05-10
NO3033357T3 (hr) 2018-07-14
AU2014308143A1 (en) 2016-03-03
HK1224302A1 (zh) 2017-08-18
WO2015022076A1 (en) 2015-02-19
IL244135B (en) 2020-02-27
SI3033357T1 (en) 2018-07-31
IL244135A0 (en) 2016-04-21
EA035855B1 (ru) 2020-08-20
WO2015022077A1 (en) 2015-02-19
JP6775420B2 (ja) 2020-10-28
HUE038977T2 (hu) 2018-12-28
ES2668482T3 (es) 2018-05-18
EP3033357B1 (en) 2018-02-14
AU2014308143B2 (en) 2019-10-31
KR102385790B1 (ko) 2022-04-12
JP2016530256A (ja) 2016-09-29
PL3033357T3 (pl) 2018-08-31
WO2015022077A8 (en) 2015-12-03
MX2016002027A (es) 2016-05-16
US10407499B2 (en) 2019-09-10
EP2837637A1 (en) 2015-02-18
EA201690383A1 (ru) 2016-06-30
PT3033357T (pt) 2018-05-18
CL2016000349A1 (es) 2016-11-04
DK3033357T3 (en) 2018-05-22
SG11201600930RA (en) 2016-03-30
US20160185857A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
IL261743B (en) and their uses 33–il antibodies against
HK1232243A1 (zh) 抗- 抗體及其用途
IL261547B (en) Antibodies against pesidine and their uses
IL245040A0 (en) Antibodies against pdgfr-beta and their uses
IL243974A0 (en) Antibodies against -prlr and uses
ZA201508896B (en) Anti-c10orf54 antibodies and uses thereof
HK1216893A1 (zh) 抗體及其用途
EP2970505A4 (en) SPECIFIC ANTIBODIES AND USES THEREOF
HK1224311A1 (zh) 受體抗原結合蛋白質及其應用
HRP20180664T1 (hr) Nova protutijela protiv receptora fc-gama iib i njihova upotreba
HK1223950A1 (zh) 單克隆 抗體及其用途
HK1210182A1 (en) Anti-prokineticin receptor (prokr) antibodies and uses thereof (prokr)